Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

AstraZeneca Company

AZN.L
GB0009895292
886455

Price

155.89
Today +/-
+1.96
Today %
+1.38 %
P

AstraZeneca stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the AstraZeneca stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AstraZeneca stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AstraZeneca stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AstraZeneca's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AstraZeneca Stock Price History

DateAstraZeneca Price
10/14/2024155.89 undefined
10/11/2024153.76 undefined
10/10/2024153.71 undefined
10/9/2024153.53 undefined
10/8/2024153.04 undefined
10/7/2024154.52 undefined
10/4/2024154.06 undefined
10/3/2024156.98 undefined
10/2/2024158.51 undefined
10/1/2024156.76 undefined
9/30/2024154.99 undefined
9/27/2024155.85 undefined
9/26/2024157.22 undefined
9/25/2024154.07 undefined
9/24/2024154.53 undefined
9/23/2024154.62 undefined
9/20/2024156.92 undefined
9/19/2024158.08 undefined
9/18/2024156.62 undefined
9/17/2024157.50 undefined
9/16/2024158.80 undefined

AstraZeneca Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AstraZeneca, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AstraZeneca from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AstraZeneca’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AstraZeneca. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AstraZeneca’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AstraZeneca’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AstraZeneca’s growth potential.

AstraZeneca Revenue, EBIT and net profit per share

DateAstraZeneca RevenueAstraZeneca EBITAstraZeneca Net Income
2029e70.54 B undefined0 undefined21.6 B undefined
2028e65.74 B undefined24.65 B undefined18.83 B undefined
2027e63.26 B undefined23.19 B undefined17.83 B undefined
2026e61.42 B undefined20.55 B undefined16.35 B undefined
2025e57.8 B undefined17.98 B undefined15.04 B undefined
2024e53.72 B undefined15.43 B undefined12.98 B undefined
202345.81 B undefined8.92 B undefined5.96 B undefined
202244.35 B undefined8.83 B undefined3.29 B undefined
202137.42 B undefined4.9 B undefined112 M undefined
202026.62 B undefined4.4 B undefined3.2 B undefined
201924.38 B undefined3.79 B undefined1.34 B undefined
201822.09 B undefined2.43 B undefined2.16 B undefined
201722.47 B undefined3.84 B undefined3 B undefined
201623 B undefined4.1 B undefined3.5 B undefined
201524.71 B undefined5.52 B undefined2.83 B undefined
201426.55 B undefined5.17 B undefined1.23 B undefined
201325.71 B undefined6.8 B undefined2.56 B undefined
201227.97 B undefined9.45 B undefined6.3 B undefined
201133.59 B undefined12.99 B undefined9.98 B undefined
201033.27 B undefined13.2 B undefined8.05 B undefined
200932.8 B undefined11.93 B undefined7.52 B undefined
200831.6 B undefined10.09 B undefined6.1 B undefined
200729.56 B undefined8.31 B undefined5.6 B undefined
200626.48 B undefined8.05 B undefined6.04 B undefined
200523.95 B undefined6.5 B undefined4.71 B undefined
200421.43 B undefined4.55 B undefined3.65 B undefined

AstraZeneca Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
6.936.986.676.867.738.378.519.1318.4518.116.4817.8418.8521.4323.9526.4829.5631.632.833.2733.5927.9725.7126.5524.712322.4722.0924.3826.6237.4244.3545.8153.7257.861.4263.2665.7470.54
-0.81-4.532.8812.728.281.707.27102.03-1.85-8.978.265.6513.6711.7810.5411.656.913.811.420.97-16.72-8.093.25-6.93-6.90-2.33-1.6710.389.1640.5818.533.2917.267.606.272.993.917.31
60.5859.2657.5455.8757.0858.0561.9360.9467.4769.7372.9674.6776.2975.7677.6479.0079.6980.4082.9781.2382.2281.2180.0378.9581.8482.4281.3980.7880.2280.2074.5080.5082.39------
4.24.143.843.834.414.865.275.5612.4512.6212.0213.3214.3816.2318.5920.9223.5625.4127.2227.0227.6222.7220.5820.9620.2218.9618.2917.8419.5621.3527.8835.737.74000000
1.120.61.061.011.311.631.781.823.914.334.164.364.114.556.58.058.3110.0911.9313.212.999.456.85.175.524.13.842.433.794.44.98.838.9215.4317.9820.5523.1924.650
16.198.5215.8614.7116.9219.4520.8619.9121.1923.9225.2224.4221.8121.2227.1530.4228.1131.9236.3539.6938.6833.7626.4419.4722.3417.8217.0811.0215.5316.5313.1019.9019.4628.7231.1133.4636.6537.50-
0.610.140.650.680.5311.21.181.142.542.972.843.043.654.716.045.66.17.528.059.986.32.561.232.833.532.161.343.20.113.295.9612.9815.0416.3517.8318.8321.6
--76.97362.144.79-21.8389.2519.24-1.09-3.38122.0516.90-4.427.0520.2628.9028.41-7.419.0423.277.0723.97-36.92-59.41-51.76129.1223.86-14.23-28.19-38.05139.40-96.502,835.7181.11117.9515.868.749.005.6614.68
---------------------------------------
---------------------------------------
0.720.720.840.950.950.950.950.951.781.771.761.741.711.681.621.571.51.451.451.451.371.261.251.261.271.271.271.271.31.311.431.561.56000000
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The AstraZeneca Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AstraZeneca is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                               
0.631.551.151.231.671.20.613.294.453.824.693.955.236.67.766.044.6711.412.5511.828.5210.017.166.855.94.555.686.227.996.46.415.96
1.862.192.192.332.362.32.512.912.662.392.653.24.773.764.295.335.565.786.256.635.75.514.764.632.582.833.813.966.327.518.86
00000000.730.540.660.670.5400.551.872.93.64.073.712.291.641.291.40.961.421.471.351.371.72.472.423.08
1.261.151.221.321.171.21.322.162.112.42.593.023.022.212.252.121.641.751.681.852.061.911.962.142.333.042.893.194.028.984.75.42
00000000.830.750.581.532.2200.640.770.70.680.750.940.911.131.611.421.421.031.292.680.971.882.071.571.73
3.764.894.564.885.24.74.459.9110.529.8512.1312.9313.0313.7716.9417.0816.1523.7625.1323.5119.0520.3416.716.0113.2613.1515.5915.5619.5426.2422.5925.05
2.352.492.712.933.123.213.625.984.965.416.67.548.16.997.458.37.047.316.966.436.095.826.016.416.857.627.428.348.9210.179.4510.5
0.050.040.060.060.20.20.240.190.010.020.050.220.260.260.120.180.160.180.210.20.20.280.560.540.831.040.921.461.151.241.141.68
000000000000000000000.351.871.110.910.90.850.520.350.330.50.590.53
00000002.652.11.871.952.053.051.763.1111.4712.3212.2312.1610.9816.4516.0520.9822.6527.5926.1921.9620.8320.9542.3939.3138.09
0000.030.040.130.641.090.850.830.850.8300.951.19.889.879.899.879.869.99.9811.5511.811.6611.8311.7111.6711.852019.8220.05
0000000000001.591.121.221.041.241.551.81.861.51.571.681.741.452.692.543.1744.823.585.22
2.42.522.783.023.363.554.59.97.928.139.4510.641311.071330.8830.6331.163129.3234.4935.5641.944.0549.2650.245.0645.8147.1979.1273.8976.07
6.167.417.337.98.568.258.9519.8218.4317.9921.5823.5726.0324.8429.9347.9646.7854.9256.1352.8353.5355.958.660.0662.5363.3560.6561.3866.73105.3696.48101.12
                                                               
272348370367406390394444442436429423411395383364362363352323312315316316316317317328328387387388
000.010.010.020.040.050.20.240.330.40.450.550.691.671.892.052.182.673.083.53.984.264.34.354.394.437.947.9735.1335.1635.19
-0.191.862.262.513.063.133.719.668.849.0210.3412.3113.4612.5113.2512.5313.518.1220.1919.8519.9218.9315.0513.8710.1910.257.724.867.323.761.53.57
861069116117800000000000000000000000897130-1,6040
00000000000000000000000000000000
0.172.322.733.053.663.564.1610.39.529.7911.1713.1814.4313.615.314.7815.9120.6623.2123.2523.7423.2219.6318.4914.8514.9612.4713.1316.5239.435.4339.14
1.751.972.042.092.010.870.971.6132.393.173.0903.163.483.53.94.935.15.444.945.353.493.472.993.611.721.772.352.822.553.27
1.8400000.370.431.80.830.721.021.2401.121.652.612.252.722.622.823.433.813.433.193.13.795.155.094.998.088.38.86
0.120.510.590.630.81.521.643.232.853.063.513.216.452.474.184.86.188.078.955.514.645.17.967.296.866.737.679.2510.589.89.913.01
22514932637436827324334412621420215214284114140163908713710522219618994152160154370387350515
0.020.860.020.040.020.040.040.040.090.110.31000.010.024.140.831.840.041.850.81.572.250.732.212.11.591.862.021.515.194.89
3.953.482.973.143.23.073.317.026.96.488.227.76.596.849.4515.1913.3217.6416.7915.7513.916.0517.3314.8715.2616.3816.2918.1220.3122.5926.2930.54
0.050.820.810.830.820.860.761.20.930.790.360.361.11.111.0910.8810.869.149.17.349.418.598.414.1414.515.5617.3616.2217.9928.8923.6923.22
00000000001.211.591.981.111.564.123.133.253.152.742.582.831.82.673.9643.292.492.926.212.942.84
1.990.790.820.880.880.710.661.251.070.90.560.681.852.092.422.863.424.083.693.533.695.1811.439.8812.1410.779.679.969.878.396.55.35
2.041.611.631.711.71.571.422.4621.682.142.624.924.315.0717.8617.416.4615.9313.6115.6816.621.6226.6830.630.3330.3228.6630.7843.4833.1331.41
5.995.094.64.854.94.644.749.478.898.1610.3510.3211.5111.1514.5233.0430.7234.132.7229.3629.5832.6538.9541.5545.8646.7146.6146.7851.0966.0859.4361.95
6.167.417.337.898.568.28.8919.7818.4117.9521.5223.4925.9424.7529.8247.8246.6454.7655.9352.653.3255.8758.5860.0460.7161.6759.0859.9167.61105.4794.86101.1
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of AstraZeneca provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AstraZeneca's financial health and stability.

Assets

AstraZeneca's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AstraZeneca must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AstraZeneca after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AstraZeneca's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
001.061.221.411.631.781.823.914.334.164.364.114.556.678.547.988.6810.8110.9812.377.723.271.253.073.552.231.991.553.92-0.272.56.9
000.260.270.310.340.350.411.070.990.860.961.291.271.331.351.862.622.092.742.552.524.583.282.852.363.043.753.763.156.535.485.39
000000000000000000000000000000000
1.051.07-0.17-0.37-0.54-0.67-0.71-0.53-1.21-0.97-1.64-0.46-1.91-1.32-1.31-2.13-3.34-3.11-1.69-3.09-5.44-3.29-1.150.77-1.9-0.16-1.2-1.85-2.24-1.93-0.431.37-2.6
00-0.17-0.11-0.14-0.1-0.13-0.21-1.65-0.8-0.25-0.03-0.070.330.06-0.061.010.550.540.05-1.650.010.71.76-0.7-1.6-0.48-1.28-0.1-0.330.130.460.66
0.230.130.210.130.10.110.110.10.10.150.080.10.030.070.030.070.340.690.640.640.550.550.480.530.50.680.70.680.770.730.720.851.08
000.170.250.440.450.520.471.020.650.790.80.891.251.612.172.562.212.382.5342.040.841.21.350.410.450.541.121.561.741.622.37
1.051.070.981.021.031.191.31.492.133.553.134.833.424.826.747.697.518.7411.7410.687.826.957.47.063.324.153.582.622.974.85.969.8110.35
-363-470-470-482-440-582-749-843-2,753-1,460-1,582-1,609-1,515-1,278-967-1,339-1,679-4,039-1,586-2,181-1,297-4,619-2,058-2,752-2,788-2,314-1,620-1,371-2,460-2,606-2,200-2,571-3,778
-192-309-395-441-439-499-569-905-1,007-1,294-1,327-2,350-746970-1,182-272-14,887-3,896-2,476-2,340-2,022-1,859-2,889-7,032-4,239-3,969-2,328963-657-285-11,058-2,960-4,064
0.170.160.080.0400.080.18-0.061.750.170.26-0.740.772.25-0.221.07-13.210.14-0.89-0.16-0.732.76-0.83-4.28-1.45-1.66-0.712.331.82.32-8.86-0.39-0.29
000000000000000000000000000000000
-0.010.11-1.28-0.790.08-0.03-0.05-0.06-0.02-0.070.04-0.12-0.350.7300.0212.64-3.17-0.79-1.750.050.9-0.030.654.372.170.561.47-1.71.447.65-1.44-1.23
002.030.010.010.010.030.01-0.16-0.33-0.99-1.15-1.11-2.11-2.86-3.16-3.95-0.450.14-2.11-5.61-2.210.480.280.040.050.040.033.530.030.030.030.03
-0.82-0.720.42-1.19-0.37-0.54-0.61-0.77-1.4-1.62-2.2-2.51-2.67-2.76-4.57-5.376.05-6.36-3.63-7.22-9.32-4.92-3.05-2.710.88-1.32-2.94-2.04-1.77-2.23.65-6.82-6.57
-788-828-1820-21-34-26-109000000000000348-36-116-5118-20-674-101-178-1,047-886
-260-149-403-432-476-559-613-1,216-1,220-1,236-1,234-1,222-1,378-1,717-2,220-2,641-2,739-2,977-3,361-3,764-3,665-3,461-3,521-3,486-3,561-3,519-3,484-3,592-3,572-3,856-4,364-4,481
0.040.041-0.620.230.160.12-0.19-0.280.64-0.4-0.02-03.060.972.09-1.26-1.65.711.15-3.550.161.4-2.83-0.11-1.13-1.751.50.552.32-1.51-0.06-0.35
687597507533590612550648-6282,0941,5443,2241,9013,5395,7766,3545,8314,70310,1538,4996,5242,3295,3424,3065361,8311,9581,2475092,1933,7637,2376,567
000000000000000000000000000000000

AstraZeneca stock margins

The AstraZeneca margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AstraZeneca. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AstraZeneca.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AstraZeneca's sales revenue. A higher gross margin percentage indicates that the AstraZeneca retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AstraZeneca's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AstraZeneca's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AstraZeneca's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AstraZeneca. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AstraZeneca's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AstraZeneca Margin History

AstraZeneca Gross marginAstraZeneca Profit marginAstraZeneca EBIT marginAstraZeneca Profit margin
2029e82.39 %0 %30.62 %
2028e82.39 %37.5 %28.65 %
2027e82.39 %36.65 %28.18 %
2026e82.39 %33.46 %26.62 %
2025e82.39 %31.11 %26.02 %
2024e82.39 %28.72 %24.16 %
202382.39 %19.46 %13 %
202280.5 %19.9 %7.41 %
202174.5 %13.1 %0.3 %
202080.2 %16.53 %12.01 %
201980.22 %15.53 %5.47 %
201880.78 %11.02 %9.76 %
201781.39 %17.08 %13.36 %
201682.42 %17.82 %15.21 %
201581.84 %22.34 %11.43 %
201478.95 %19.47 %4.64 %
201380.03 %26.44 %9.94 %
201281.21 %33.76 %22.51 %
201182.22 %38.68 %29.72 %
201081.23 %39.69 %24.21 %
200982.97 %36.35 %22.93 %
200880.4 %31.92 %19.31 %
200779.69 %28.11 %18.93 %
200679 %30.42 %22.83 %
200577.64 %27.15 %19.65 %
200475.76 %21.22 %17.04 %

AstraZeneca Stock Sales Revenue, EBIT, Earnings per Share

The AstraZeneca earnings per share therefore indicates how much revenue AstraZeneca has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AstraZeneca earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AstraZeneca's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AstraZeneca’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AstraZeneca's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AstraZeneca Revenue, EBIT and net profit per share

DateAstraZeneca Sales per ShareAstraZeneca EBIT per shareAstraZeneca Earnings per Share
2029e45.5 undefined0 undefined13.93 undefined
2028e42.4 undefined0 undefined12.15 undefined
2027e40.81 undefined0 undefined11.5 undefined
2026e39.62 undefined0 undefined10.55 undefined
2025e37.28 undefined0 undefined9.7 undefined
2024e34.65 undefined0 undefined8.37 undefined
202329.33 undefined5.71 undefined3.81 undefined
202228.43 undefined5.66 undefined2.11 undefined
202126.22 undefined3.44 undefined0.08 undefined
202020.27 undefined3.35 undefined2.43 undefined
201918.74 undefined2.91 undefined1.03 undefined
201817.43 undefined1.92 undefined1.7 undefined
201717.73 undefined3.03 undefined2.37 undefined
201618.17 undefined3.24 undefined2.76 undefined
201519.53 undefined4.36 undefined2.23 undefined
201421 undefined4.09 undefined0.98 undefined
201320.5 undefined5.42 undefined2.04 undefined
201222.13 undefined7.47 undefined4.98 undefined
201124.57 undefined9.5 undefined7.3 undefined
201023.01 undefined9.13 undefined5.57 undefined
200922.62 undefined8.22 undefined5.19 undefined
200821.75 undefined6.94 undefined4.2 undefined
200719.73 undefined5.55 undefined3.73 undefined
200616.86 undefined5.13 undefined3.85 undefined
200514.8 undefined4.02 undefined2.91 undefined
200412.79 undefined2.71 undefined2.18 undefined

AstraZeneca business model

AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.com.

AstraZeneca SWOT Analysis

Strengths

AstraZeneca PLC has several strengths that contribute to its success:

  • Strong brand reputation globally
  • Wide range of innovative pharmaceutical products
  • Robust research and development capabilities
  • Extensive global presence and distribution network
  • Strong financial performance and stability

Despite its strengths, AstraZeneca PLC also faces certain weaknesses:

  • Reliance on a limited number of key products
  • Patent expirations and generic competition
  • Regulatory challenges and approval process delays
  • Higher pricing compared to competitors

AstraZeneca PLC can leverage the following opportunities to further its growth:

  • Increasing demand for personalized medicine
  • Expanding presence in emerging markets
  • Collaboration and partnerships with healthcare providers
  • Advancements in technology for drug discovery and development

AstraZeneca PLC should be cautious of the following potential threats:

  • Intense competition within the pharmaceutical industry
  • Economic downturns impacting healthcare spending
  • Stringent regulations and compliance requirements
  • Risks associated with clinical trials and drug safety

Weaknesses

Despite its strengths, AstraZeneca PLC also faces certain weaknesses:

  • Reliance on a limited number of key products
  • Patent expirations and generic competition
  • Regulatory challenges and approval process delays
  • Higher pricing compared to competitors

AstraZeneca PLC can leverage the following opportunities to further its growth:

  • Increasing demand for personalized medicine
  • Expanding presence in emerging markets
  • Collaboration and partnerships with healthcare providers
  • Advancements in technology for drug discovery and development

AstraZeneca PLC should be cautious of the following potential threats:

  • Intense competition within the pharmaceutical industry
  • Economic downturns impacting healthcare spending
  • Stringent regulations and compliance requirements
  • Risks associated with clinical trials and drug safety

Opportunities

AstraZeneca PLC can leverage the following opportunities to further its growth:

  • Increasing demand for personalized medicine
  • Expanding presence in emerging markets
  • Collaboration and partnerships with healthcare providers
  • Advancements in technology for drug discovery and development

AstraZeneca PLC should be cautious of the following potential threats:

  • Intense competition within the pharmaceutical industry
  • Economic downturns impacting healthcare spending
  • Stringent regulations and compliance requirements
  • Risks associated with clinical trials and drug safety

Threats

AstraZeneca PLC should be cautious of the following potential threats:

  • Intense competition within the pharmaceutical industry
  • Economic downturns impacting healthcare spending
  • Stringent regulations and compliance requirements
  • Risks associated with clinical trials and drug safety

AstraZeneca Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AstraZeneca historical P/E ratio, EBIT multiple, and P/S ratio

AstraZeneca shares outstanding

The number of shares was AstraZeneca in 2023 — This indicates how many shares 1.562 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue AstraZeneca earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AstraZeneca's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AstraZeneca’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AstraZeneca's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AstraZeneca stock splits

In AstraZeneca's history, there have been no stock splits.

AstraZeneca dividend history and estimates

In 2023, AstraZeneca paid a dividend amounting to 2.35 USD. Dividend means that AstraZeneca distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for AstraZeneca provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify AstraZeneca’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating AstraZeneca's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

AstraZeneca Dividend History

DateAstraZeneca Dividend
2029e0.6 undefined
2028e0.7 undefined
2027e0.54 undefined
2026e0.56 undefined
2025e1.01 undefined
2024e0.05 undefined
20232.35 undefined
20222.22 undefined
20212.02 undefined
20202.16 undefined
20192.19 undefined
20182.02 undefined
20172.19 undefined
20162.14 undefined
20152.03 undefined
20141.89 undefined
20133.11 undefined
20123.17 undefined
20113 undefined
20102.68 undefined
20092.32 undefined
20082.11 undefined
20071.94 undefined
20061.57 undefined
20051.14 undefined
20040.93 undefined

AstraZeneca dividend payout ratio

In 2023, AstraZeneca had a payout ratio of 923.35%. The payout ratio indicates the percentage of the company's profits that AstraZeneca distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for AstraZeneca represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for AstraZeneca could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate AstraZeneca's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

AstraZeneca Payout Ratio History

DateAstraZeneca Payout ratio
2029e937.3 %
2028e888.82 %
2027e967 %
2026e956.09 %
2025e743.36 %
2024e1,201.55 %
2023923.35 %
2022105.19 %
20212,576.12 %
202088.74 %
2019213.13 %
2018118.76 %
201792.84 %
201677.52 %
201590.8 %
2014193.53 %
2013152.51 %
201263.59 %
201141.1 %
201048.08 %
200944.74 %
200850.26 %
200752.13 %
200640.69 %
200539.14 %
200442.56 %
Unfortunately, there are currently no price targets and forecasts available for AstraZeneca.

AstraZeneca latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20242.02 1.98  (-1.9 %)2024 Q2
3/31/20241.96 2.06  (4.9 %)2024 Q1
12/31/20231.53 1.45  (-5.01 %)2023 Q4
9/30/20231.67 1.73  (3.81 %)2023 Q3
6/30/20232.01 2.15  (6.81 %)2023 Q2
3/31/20231.77 1.92  (8.77 %)2023 Q1
12/31/20221.33 1.38  (3.94 %)2022 Q4
9/30/20221.57 1.67  (6.48 %)2022 Q3
6/30/20221.61 1.72  (6.99 %)2022 Q2
3/31/20221.74 1.89  (8.32 %)2022 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the AstraZeneca stock

Eulerpool World ESG Rating (EESG©)

93/ 100

🌱 Environment

91

👫 Social

97

🏛️ Governance

92

Environment

Scope 1 - Direct Emissions
180,898
Scope 2 - Indirect emissions from purchased energy
183,332
Scope 3 - Indirect emissions within the value chain
6,736,878
Total CO₂ emissions
364,230
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
❌
Pesticides
—
Palm Oil
❌
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees53.9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AstraZeneca shareholders

%
Name
Stocks
Change
Date
6.50750 % BlackRock Investment Management (UK) Ltd.100,885,18101/31/2024
4.20056 % Wellington Management Company, LLP65,120,89201/31/2024
3.32762 % Investor AB51,587,81001/31/2024
3.06963 % Capital Research Global Investors47,588,113-110,56212/13/2023
2.97650 % The Vanguard Group, Inc.46,144,351973,26212/13/2023
2.21948 % Norges Bank Investment Management (NBIM)34,408,444-58,2193/1/2024
2.18009 % Capital World Investors33,797,748818,43412/13/2023
1.13785 % BlackRock Advisors (UK) Limited17,640,007-1,294,0913/1/2024
1.07038 % GQG Partners, LLC16,593,934709,08212/13/2023
0.90786 % BlackRock Institutional Trust Company, N.A.14,074,535160,2523/1/2024
1
2
3
4
5
...
10

AstraZeneca Executives and Management Board

Mr. Pascal Soriot63
AstraZeneca Chief Executive Officer, Executive Director (since 2012)
Compensation 15.32 M
Mr. Marc Dunoyer
AstraZeneca Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca (since 2013)
Compensation 5.66 M
Ms. Aradhana Sarin
AstraZeneca Chief Financial Officer, Executive Director (since 2021)
Compensation 2.74 M
Mr. Philip Broadley
AstraZeneca Senior Non-Executive Independent Director
Compensation 200,000
Mr. Michel Demare66
AstraZeneca Non-Executive Independent Chairman of the Board
Compensation 158,000
1
2
3
4
...
5

AstraZeneca Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Farmacias Benavides B Stock
Farmacias Benavides B
SupplierCustomer-0,19----
Access Intelligence Stock
Access Intelligence
SupplierCustomer---0,11-0,65-0,55-
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,92-0,250,610,450,48-0,34
Sun Pharmaceutical Inds Stock
Sun Pharmaceutical Inds
SupplierCustomer0,880,860,760,780,710,61
Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals
SupplierCustomer0,870,700,490,700,530,81
ON24 Stock
ON24
SupplierCustomer0,870,81-0,15-0,81-0,51-
Guardant Health Stock
Guardant Health
SupplierCustomer0,870,690,04-0,61-0,64-0,80
Talend SA Stock
Talend SA
SupplierCustomer0,850,140,830,530,55-
Merck & Co Stock
Merck & Co
SupplierCustomer0,840,050,820,840,810,79
GMR Infrastructure Stock
GMR Infrastructure
SupplierCustomer0,820,89-0,01-0,520,310,56
1
2
3
4
5
...
18

Most common questions regarding AstraZeneca

What values and corporate philosophy does AstraZeneca represent?

AstraZeneca PLC represents values of innovation, integrity, and patient-centricity in its corporate philosophy. As a leading global pharmaceutical company, AstraZeneca is dedicated to transforming the lives of patients through scientific advancements and breakthrough treatments. The company is committed to ethical business practices, ensuring transparency and accountability in all its operations. With a focus on collaboration and strategic partnerships, AstraZeneca aims to address unmet medical needs and improve healthcare worldwide. By combining cutting-edge research and a patient-first approach, AstraZeneca continues to pave the way for the development of innovative and life-saving medicines.

In which countries and regions is AstraZeneca primarily present?

AstraZeneca PLC is primarily present in multiple countries and regions across the globe. The company operates in the United States, United Kingdom, Sweden, France, Germany, China, Brazil, Canada, Japan, and many others. With a robust global footprint, AstraZeneca PLC's presence spans across North America, Europe, Asia-Pacific, Latin America, and the Middle East. As a renowned pharmaceutical company, AstraZeneca PLC delivers innovative medicines and healthcare solutions to enhance patient lives worldwide.

What significant milestones has the company AstraZeneca achieved?

AstraZeneca PLC, a renowned pharmaceutical company, has achieved several significant milestones. Firstly, they have made remarkable advancements in the field of cancer treatment, particularly with drugs like Tagrisso and Lynparza, aiding patients worldwide. Secondly, AstraZeneca has developed lifesaving medications for chronic respiratory diseases, including Symbicort and Pulmicort, improving the quality of life for millions. Furthermore, AstraZeneca's COVID-19 vaccine, developed in collaboration with the University of Oxford, has played a pivotal role in combating the global pandemic. Their dedication to scientific innovation and commitment to global health has positioned AstraZeneca PLC as a prominent leader in the pharmaceutical industry.

What is the history and background of the company AstraZeneca?

AstraZeneca PLC is a renowned British-Swedish multinational pharmaceutical and biopharmaceutical company. Established in 1999 through a merger, AstraZeneca has a rich history dating back to the 19th century. The company specializes in innovative prescription medicines, biologics, and oncology therapies that improve the health and well-being of millions of people worldwide. AstraZeneca is dedicated to developing groundbreaking treatments for various therapeutic areas, including cardiovascular, respiratory, metabolic, and autoimmune diseases, as well as cancer. With a steadfast commitment to research and development, AstraZeneca continues to make significant contributions to the global healthcare industry, improving patients' lives and advancing medical science.

Who are the main competitors of AstraZeneca in the market?

AstraZeneca PLC's main competitors in the market include pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Novartis. These companies also operate in the healthcare sector and offer a wide range of prescription drugs, vaccines, and consumer health products. However, AstraZeneca PLC has carved a niche for itself with its innovative research and development initiatives, particularly in the field of oncology and respiratory diseases. Their commitment to addressing unmet medical needs differentiates them from competitors in the pharmaceutical industry.

In which industries is AstraZeneca primarily active?

AstraZeneca PLC is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of AstraZeneca?

AstraZeneca PLC operates under a pharmaceutical business model. As a global biopharmaceutical company, AstraZeneca focuses on discovering, developing, and commercializing prescription medicines. The company is dedicated to improving patients' health and well-being through innovative treatments in therapeutic areas such as oncology, respiratory, cardiovascular, and more. AstraZeneca engages in extensive research and development (R&D) activities to develop new drugs and therapies, collaborating with academic institutions, healthcare providers, and other industry partners. With a strong emphasis on scientific innovation, AstraZeneca aims to address unmet medical needs and deliver value to patients and healthcare systems worldwide.

What is the P/E ratio of AstraZeneca 2024?

The AstraZeneca P/E ratio is 18.76.

What is the P/S ratio of AstraZeneca 2024?

The AstraZeneca P/S ratio is 4.53.

What is the Quality Investing of AstraZeneca?

The Quality Investing for AstraZeneca is 7/10.

What is the revenue of AstraZeneca 2024?

The expected AstraZeneca revenue is 53.72 B USD.

How high is the profit of AstraZeneca 2024?

The expected AstraZeneca profit is 12.98 B USD.

What is the business model of AstraZeneca

AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications in the fields of cancer, cardiovascular, respiratory, immunology, and infectious diseases. It was founded in 1999 by the merger of Astra AB and Zeneca Group plc. The company is headquartered in London, UK, and employs over 70,000 employees in 100 countries worldwide. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. The company's focus is on developing and marketing innovative medications for treating a variety of diseases and conditions. IMED is AstraZeneca's key business segment and encompasses the research and development of new medications. This includes innovative active substances and therapies that have the potential to fundamentally improve disease treatment. Some current research focuses include cancer therapy, immunology, respiratory diseases, and cardiovascular diseases. GPPS is responsible for the marketing and portfolio management of AstraZeneca's pharmaceuticals. This includes strategic decision-making regarding which medications should continue to be developed and brought to market. GPPS also has responsibility for the distribution channels and pricing strategy of medications, ensuring both the company's profitability and the availability of medications for patients worldwide. BioPharmaceuticals is another important business segment of AstraZeneca, focusing on the production, distribution, and marketing of medications. This primarily includes biological therapies used for the treatment of cancer, inflammatory diseases, and autoimmune diseases. Some of AstraZeneca's most well-known medications include Nexium, a treatment for gastric ulcers and heartburn; Crestor, a cholesterol-lowering drug; and Symbicort, an inhaler for the treatment of asthma and chronic bronchitis. Additionally, AstraZeneca is actively involved in developing new medications, including promising cancer therapies such as Tagrisso, Lynparza, and Imfinzi. An essential part of AstraZeneca's business model is collaboration with other companies and institutions through partnerships and cooperation. Through targeted collaborations and acquisitions, the company expands its portfolio of medications and strengthens its position in the competition. Overall, AstraZeneca's business model is focused on developing, manufacturing, and marketing innovative and effective medications to achieve improvements in patient care and treatment, thereby contributing to the well-being of society. Output: AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications. It was founded in 1999 and is headquartered in London, UK. The company employs over 70,000 employees in 100 countries. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. IMED focuses on research and development of new medications, while GPPS handles marketing and portfolio management. BioPharmaceuticals focuses on production, distribution, and marketing. AstraZeneca is known for medications such as Nexium, Crestor, and Symbicort. The company collaborates with other companies and institutions through partnerships and cooperation. Overall, AstraZeneca aims to develop, manufacture, and market effective medications to improve patient care and contribute to society.

What is the AstraZeneca dividend?

AstraZeneca pays a dividend of 2.22 USD distributed over 2 payouts per year.

How often does AstraZeneca pay dividends?

AstraZeneca pays out a dividend 2 times a year.

What is the AstraZeneca ISIN?

The ISIN of AstraZeneca is GB0009895292.

What is the AstraZeneca WKN?

The WKN of AstraZeneca is 886455.

What is the AstraZeneca ticker?

The ticker of AstraZeneca is AZN.L.

How much dividend does AstraZeneca pay?

Over the past 12 months, AstraZeneca paid a dividend of 2.35 USD . This corresponds to a dividend yield of about 1.5 %. For the coming 12 months, AstraZeneca is expected to pay a dividend of 1.01 USD.

What is the dividend yield of AstraZeneca?

The current dividend yield of AstraZeneca is 1.5 %.

When does AstraZeneca pay dividends?

AstraZeneca pays a quarterly dividend. This is distributed in the months of March, September, March, September.

How secure is the dividend of AstraZeneca?

AstraZeneca paid dividends every year for the past 26 years.

What is the dividend of AstraZeneca?

For the upcoming 12 months, dividends amounting to 1.01 USD are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is AstraZeneca located?

AstraZeneca is assigned to the 'Health' sector.

Wann musste ich die Aktien von AstraZeneca kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AstraZeneca from 9/9/2024 amounting to 0.776 USD, you needed to have the stock in your portfolio before the ex-date on 8/8/2024.

When did AstraZeneca pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of AstraZeneca in the year 2023?

In the year 2023, AstraZeneca distributed 2.217 USD as dividends.

In which currency does AstraZeneca pay out the dividend?

The dividends of AstraZeneca are distributed in USD.

All fundamentals about AstraZeneca

Our stock analysis for AstraZeneca Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AstraZeneca Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.